Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
US11390666B2 · kind B2 · utility
0Cited by
14References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 6, 2018 |
| Grant date | Jul 19, 2022 |
| Priority date | — |
| Expiry date | Jun 6, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application relates to a fusion protein comprising an antibody molecule, or antigen-binding fragment thereof, and a member of the vascular endothelial growth factor family, such as VEGF-C or VEGF-D. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the application relates to the therapeutic use of such fusion protein in the treatment of an inflammatory disease or disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.